Sociedad Americana de Hirudoterapia

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis.

Review published in The Annals of thoracic surgery (2000)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosDesarrollo de fármacosFollis et al. · The Annals of thoracic surgery, 2000

Abstract

Heparin-induced thrombocytopenia and thrombosis (HITT) is an immunomediated disorder induced by the administration of heparin for therapeutic purposes. The presence of this condition in patients requiring full heparinization for cardiopulmonary bypass constitutes a formidable challenge for the cardiac surgeon. In this review, the clinical and experimental experience described in the literature are discussed in the perspective of the normal coagulation and the pathophysiology of HITT and in the light of a variety of old and new alternative anticoagulants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsBlood Coagulation TestsCardiopulmonary BypassHeparinHumansThrombocytopeniaThrombosis

Resumen

Heparin-induced thrombocytopenia and thrombosis (HITT) is an immunomediated disorder induced by the administration of heparin for therapeutic purposes. The presence of this condition in patients requiring full heparinization for cardiopulmonary bypass constitutes a formidable challenge for the cardiac surgeon.

Por qué esto importa para la hirudoterapia

This review discusses the clinical challenge of performing cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis (HITT), an immunomediated disorder caused by heparin administration. The authors review clinical and experimental experience with various old and new alternative anticoagulants, framed within the context of normal coagulation physiology and HITT pathophysiology. The abstract does not mention leeches, hirudin, leech-derived molecules, or hirudotherapy at any point. Consequently, the article has no direct connection to the American Society of Hirudotherapy's domain based on the abstract, and any relevance would be limited to general background on anticoagulation management that does not specifically involve leech-based therapies.

Citación

Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis.

Follis et al. · The Annals of thoracic surgery, 2000

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.